You may have seen that Lumosity was fined $50 million last week.
“Lumosity preyed on consumers’ fears about age-related cognitive decline, suggesting their games could stave off memory loss, dementia, and even Alzheimer’s disease,” Jessica Rich, director of the FTC’s Bureau of Consumer Protection, said in a written statement. “But Lumosity simply did not have the science to back up its ads.”
The FTC suspended all but $2 million of that (because Lumosity didn’t have $50 million), but the point was still made.
By contrast, the BrainHQ exercises that I pitch you from time to time, do have the science.
. . . Its exercises have been rigorously tested and scientifically proven to work in more than 100 independent, peer-reviewed research papers published in scientific journals . . . BrainHQ has been shown to bring substantial improvements in each of these categories:
Whereupon it lists, with links to those studies, processing speed (e.g, “A doubling, on average, in visual processing speed, with some benefit of training still evident at 5- and 10-year follow-ups”); memory (“an average improvement of 10 years”); driving (“can stop 22 feet sooner when driving 55 mph”) and half a dozen other metrics, like balance and fall risk.
So if you were among the millions paying Lumosity $14.95/month — or thinking that crossword puzzles are likely as effective (they’re not) — you might want to give BrainHQ’s free exercises a try. And then, perhaps — be still, my greedy little heart, as I have a small stake in the company — even sign up for their full suite.
Quote of the Day
Not all of us can be born rich, handsome, and lucky, and that's why we have a Democratic Party.~Senator Zell Miller before he lost his mind
Request email delivery
- Oct 18:
Gregg Popovich: Teaching Software To Write Software
- Oct 17:
Hurtling Toward The Future
- Oct 16:
He’s Baaaaaack . . .
- Oct 13:
Mikey’s Last Breakfast
- Oct 12:
- Oct 11:
Why Corporate Tax Cuts Won’t Create Jobs
- Oct 10:
A Letter From Secretary Albright
- Oct 9:
- Oct 6:
- Oct 5:
The Kids Pay The Price
- Oct 18: